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If misregulated, macrophage (Mϕ)–T cell interactions can drive chronic inflammation thereby 
causing diseases, such as rheumatoid arthritis (RA). We report that in a proinflammatory 
environment, granulocyte-Mϕ (GM-CSF)- and Mϕ colony-stimulating factor (M-CSF)-
dependent Mϕs have dichotomous effects on T cell activity. While GM-CSF-dependent 
Mϕs show a highly stimulatory activity typical for M1 Mϕs, M-CSF-dependent Mϕs, 
marked by folate receptor β (FRβ), adopt an immunosuppressive M2 phenotype. We 
find the latter to be caused by the purinergic pathway that directs release of extracellular 
ATP and its conversion to immunosuppressive adenosine by co-expressed CD39 
and CD73. Since we observed a misbalance between immunosuppressive and immu-
nostimulatory Mϕs in human and murine arthritic joints, we devised a new strategy for 
RA treatment based on targeted delivery of a novel methotrexate (MTX) formulation to 
the immunosuppressive FRβ+CD39+CD73+ Mϕs, which boosts adenosine production 
and curtails the dominance of proinflammatory Mϕs. In contrast to untargeted MTX, 
this approach leads to potent alleviation of inflammation in the murine arthritis model. 
In conclusion, we define the Mϕ extracellular purine metabolism as a novel checkpoint 
in Mϕ cell fate decision-making and an attractive target to control pathological Mϕs in 
immune-mediated diseases.
Keywords: macrophage polarization, chronic inflammation, macrophage-T cell interaction, purine metabolism, 
adenosine, methotrexate, rheumatoid arthritis
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inTrODUcTiOn
Macrophages (Mϕs) are myeloid immune cells essential for tissue 
homeostasis and immunity. Their differentiation and main tenance 
is controlled in a tissue-specific manner mainly by two growth 
factors, Mϕ and granulocyte-Mϕ colony-stimulating factor 
(M-CSF/CSF-1 and GM-CSF/CSF-2), respectively (1). In addi-
tion, the Mϕ phenotype is further shaped by local stimuli, to 
which Mϕs respond with high plasticity (2). During infection or 
sterile inflammation, proinflammatory cyto kines, such as IFNγ, 
or toll-like receptor (TLR) ligands activate Mϕs into the proin-
flammatory M1 type with microbicidal and tumoricidal activity. 
Alternatively, Th2 cytokines IL-4/IL-13 promote M2 Mϕs with 
a tissue remodeling or immunoregulatory phenotype, while 
stimulation with IL-10, transforming growth factor-β (TGF-β), or 
glucocorticoids generates highly immu nosuppressive “M2-like” 
Mϕs (3–5). The shift in the Mϕ polarizing stimuli during the 
resolution phase of infection is thought to convert M1 Mϕs to 
the M2 type, restoring tissue homeos tasis (4, 6).
Recently, it has become apparent that ligation of TLRs or 
cytokine receptors also triggers profound changes in key metabolic 
events in Mϕs, enabling coordinate induction and maintenance 
of Mϕ effector activities (7–9). In M1 Mϕs, aerobic glycolysis is 
induced to readily provide cells with energy in a form of adenosine 
5′-triphosphate (ATP). Aerobic glycolysis additionally feeds to 
the pentose phosphate pathway for production of nucleotides and 
NADPH, the latter being required for generation of microbicidal 
reactive oxygen species (8, 9). Furthermore, the glycolytic switch 
is associated with an increase in several metabolic intermediates 
that are incorporated into signaling pathways to support the 
inflammatory phenotype. In contrast, M2 Mϕs rely on oxidative 
metabolism that enables long-term cell survival and promotes 
M2 functions (7). Another example is l-arginine metabolism, 
which is a hallmark of differently polarized mouse Mϕs (10). 
In M1 Mϕs, arginine is a substrate to nitric oxide synthase (NOS2) 
induced by proinflammatory stimuli to produce antibacterial 
NO. In M2 Mϕs, arginine is metabolized by the M2 marker argi-
nase 1 (Arg1) to urea and l-ornithine, a precursor of polyamines 
important for wound healing. Additionally, Arg1 action limits 
arginine availability to bystander proliferating T cells, leading to 
their suppression (10). While these key metabolic differences 
between M1 and M2 Mϕs are widely accepted, the metabolic cues 
that control the switch between different Mϕ phenotypes are not 
well understood.
Rheumatoid arthritis (RA) is an autoimmune disease chara-
cte rized by chronic synovial inflammation and hyperplasia 
causing joint destruction (6, 11). Activated M1 Mϕs crucially 
contribute to disease pathology and their numbers in the sublin-
ing synovial layer predict severity of the disease (12). Interestingly, 
Mϕs expressing M2 markers, such as CD163 or folate receptor β 
(FRβ) were also identified in inflamed synovia (13–16). However, 
it is unclear whether and how these Mϕs with proposed anti-
inflammatory properties contribute to disease pathology or 
whether they emerge to counteract inflammation. Hence, iden-
tifying and enhancing intrinsic pathways that would contribute 
to the resolution of inflammation in RA is an unmet need in RA 
therapy.
To elucidate mechanisms how different Mϕ subtypes contri-
bute to chronic inflammation in RA and to identify pathways 
controlling their identity, we aimed to generate variously activated 
human GM-CSF- or M-CSF-differentiated Mϕs and address their 
ability to produce inflammatory mediators and influence T cell 
responses. We show that FRβ+ M-CSF-dependent Mϕs respond 
to proinflammatory stimuli by modulating gene expression of 
the purinergic pathway as a means to produce and respond to 
extracellular adenosine. Adenosine skews these cells toward the 
M2 state and suppresses autologous T cells. GM-CSF-dependent 
Mϕs resist this adenosine-mediated switch, so that only specific 
enhancement of the purinergic metabolism in the FRβ+ Mϕs 
potently limits inflammation in the arthritis mouse model.
MaTerials anD MeThODs
reagents
LPS (Escherichia coli serotype O55:B5) and adenosine were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Deuterated 
adenosine was from CDN Isotopes (Quebec, Canada). Adenosine 
5′-triphosphate disodium salt (ATP) was from Thermo Fisher 
Scientific (Waltham, MA, USA). Recombinant human M-CSF, 
IFNγ, and IL-10 were obtained from Peprotech (Rocky Hill, 
NJ, USA). Recombinant human GM-CSF and IL-4 were from 
Novartis AG (Basel, Switzerland). The RPMI 1640 medium, 
l-glutamine, streptomycin, penicillin, and heat-inactivated fetal 
calf serum (FCS) were obtained from Gibco, Thermo Fisher 
Scientific. CD39 inhibitor POM-1 was from Tocris Bioscience 
(Bristol, UK). The cell proliferation dye CFSE and calcium 
sensor Fluo-4, AM was from Molecular Probes, Thermo Fisher 
Scientific. Brilliant Violet 421-conjugated streptavidin used 
as a second step in flow cytometry analyses was purchased 
from BioLegend (San Diego, CA, USA). Phorbol 12-myristate 
13-acetate (PMA), ionomycin calcium salt (ionomycin) from 
S. conglobatus and monensin A sodium salt (monensin) were 
purchased from Sigma-Aldrich.
antibodies
The anti-FRβ monoclonal antibody (mAb) (clone EM-35) (17); 
was provided by EXBIO (Vestec, Czech Republic), either as 
purified or conjugated with Alexa Fluor 488, Alexa Fluor 647, 
or biotin. The second anti-FRβ mAb used in this study [clone 
36b (18)] was purified using a Protein A Sepharose column 
and conjugated with phycoerythrin (PE) or biotin. EXBIO also 
provided Pacific Blue-conjugated CD14 mAb (clone MEM-18), 
FITC-conjugated CD64 mAb (clone 10.1), PerCP-conjugated 
CD86 mAb (clone BU63), Alexa Fluor 700-conjugated anti-
MHC class II mAb (clone MEM-136 recognizing the β chain 
of HLA DR + DP), and allophycocyanin-conjugated CD4 mAb 
(clone MEM-241). Pacific Blue- and PE-conjugated CD69 mAb 
(clone FN50), FITC-conjugated mAbs to CD1a (clone HI149), 
CD8 (clone SK1), CD80 (clone 2D10), PE-conjugated mAb to 
CD73 (clone AD2) and to CD25 (clone BC96), PE-Cy7- and 
Brilliant Violet 421-conjugated CD39 mAb (clone A1), PerCP-
conjugated mAb to CD16 (clone 3G8), PerCP-Cy5.5-conjugated 
mAbs to CD163 (clone GHI/61) and CD209 (clone 9E9A8) 
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and allophycocyanin-Cy7-conjugated CD206 mAb (clone 15-2) 
were purchased from BioLegend. FITC-conjugated mAb to 
CD40 (clone LOB7/6) was from AbD Serotec (Oxford, UK). 
Allophycocyanin-conjugated mAb to CD25 (clone 4E3) was from 
Miltenyi Biotec (Bergisch Gladbach, Germany). For intracel-
lular staining of T  cells, the anti-FOXP3 mAb (clone 206D, 
conjugated to Alexa Fluor 647), FITC-conjugated anti-IFNγ 
mAb (clone 4S.B3), and PE-conjugated anti-IL-17A mAb (clone 
BL168) were purchased from BioLegend. The CD3 mAb OKT3 
specific for the CD3ε chain was obtained from Centocor Ortho 
Biotech (Horsham, PA, USA). The mAbs L293 to CD28 and FITC-
conjugated Leu4 to CD3 were purchased from BD Biosciences 
(Franklin Lakes, NJ, USA). mAbs to CD8 (clone MEM-87), 
CD14 (clone MEM-18), CD16 (clone MEM-154), CD19 (clone 
WIN19), CD20 (clone MEM-97), CD56 (clone MEM-188), used 
for CD4+ T cell isolation, and a CD147 mAb (clone MEM-M6/1) 
used in flow cytometry experiments were a kind gift of Vaclav 
Horejsi, Institute of Molecular Genetics, Academy of Sciences 
of the Czech Republic, Prague, Czech Republic. mAb to PD-L1 
(clone 5-OM496) was a kind gift of Otto Majdic, Institute of 
Immunology, Medical University of Vienna, Vienna, Austria. 
Allophycocyanin-conjugated goat anti-mouse IgG  +  IgM Ab 
used as the second step in flow cytometry experiments was 
from Jackson ImmunoResearch Laboratories (West Grove, PA, 
USA). Additionally, Beriglobin P (CSL Behring, King of Prussia, 
PA, USA) was used for Fc receptor blockade in flow cytometry 
experiments.
For the experiments in the mouse, rat anti-murine-FRβ mAb 
was used (19), followed by a Dylight 488-conjugated anti-rat 
secondary Ab (eBioscience, Thermo Fisher Scientific, San Diego, 
CA, USA). Anti-murine PE-Cy7-conjugated CD11b mAb (clone 
M1/70) was from BD Biosciences. PerCP-Cy5.5-conjugated F4/80 
mAb (clone BM8) and eFluor660-conjugated CD39 Ab (clone 
24DMS1) were from eBioscience. Brilliant Violet 605-conjugated 
CD73 (clone T4/11.8) was from BioLegend.
cell isolation and culture
Human blood monocytes of healthy donors were isolated and 
differentiated to Mϕs and activated as previously described (20). 
Briefly, 7-day Mϕ differentiation was induced by 25 ng/ml GM-CSF 
or 50 ng/ml M-CSF; subsequent activation by 100 ng/ml LPS plus 
25  ng/ml IFNγ, 20  ng/ml IL-4 or 20  ng/ml IL-10 for 48  h. When 
indicated, 20 µM POM-1, 100 µM ATP, 10 µM adenosine (or vehicle 
control) was added. CD4+ T  cells were isolated from monocyte-
depleted fraction by negative selection (21) and frozen. Synovial fluid 
cells were from knees of patients with inflammatory arthritis and 
analyzed immediately.
The study using human material was performed in accordance 
with the Declaration of Helsinki, informed consent was obtained 
from all participants and research was approved by the Ethics 
Committee of the Medical University of Vienna (2177/2013, 
559/2005).
T cell Proliferation assay
Activated human Mϕs, seeded in U-bottom 96-well plates 
(18,000 cells/well), were carefully washed and the autologous 
CD4+ T cells, labeled 12 h prior the assay with 1 µM CFSE, were 
added at the concentration of 90,000/well (control). In parallel, 
T  cells were polyclonally stimulated with soluble CD3 mAb 
OKT3 (1 µg/ml). Controls included T cells cultured alone with 
or without soluble CD3 mAb, or cultured with plate-bound CD3 
mAb OKT3 (1 µg/ml) plus soluble CD28 mAb L293 (0.5 µg/ml). 
In some experiments, IL-10-blocking mAb or isotype-matched 
control mAb (10  µg/ml) was included. Cocultures were per-
formed in duplicates in RPMI 1640 medium supplemented with 
2 mM l-glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin, 
and 5% heat-inactivated FCS (all from Gibco, Thermo Fisher 
Scientific); fresh medium (including mAbs) was supplemented 
every 3 days. T cell proliferation was monitored on day 7 by assess-
ing CFSE staining by flow cytometry. For quantification, T cells 
were analyzed using FlowJo (Tree Star, Ashland, OR, USA) and 
electronically sorted according to the CFSE peaks into gates that 
represented the respective generations (i) of proliferating T cells. 
Then, the cell count in the individual gates (Ni) was determined. 
The percentage of dividing T cells (from the parental population), 
%D, was calculated according to the formula:
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where i is the generation number as discriminated by the CFSE 
gating (starting with 0 for the undivided population) and Ni is 
the number of events (cells) in generation i. The division index, 
DI, defined by the average number of cell divisions that parental 
population has undergone, was calculated according to the 
formula:
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Both statistics parameters used here are explained in detail 
elsewhere (22).
Flow cytometry
Flow cytometry analysis of human Mϕs was performed as previ-
ously described (20).
For the analysis of T cell surface antigens, cells were washed 
with precooled staining buffer (PBS containing 1% BSA and 0.02% 
NaN3) and incubated on ice for 30 min with 4.8 mg/ml human 
IgG (Beriglobin P) to prevent nonspecific binding of the mAbs 
to Fc receptors. Then, antibody–fluorochrome conjugates with 
appropriate isotype controls were added. Cells were incubated 
for 30 min on ice and then washed with staining buffer. Samples 
were analyzed on an LSRII flow cytometer (BD Biosciences) 
and the data were further processed with the FlowJo software. 
Living single cells were gated according to their forward- and 
side-scatter characteristics and dead cells were excluded using 
DAPI or 7-aminoactinomycin D (Sigma-Aldrich). Cells were 
scored positively if they had a higher fluorescence than the cutoff 
of 0.5% of the isotype control mAbs. In graphs, geometric mean 
of fluorescence intensity corrected for background staining using 
matched isotype control mAb is shown.
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For FOXP3 analysis, T cells were first stained using mAbs against 
the surface markers CD4 and CD25 as described above, then 
fixed, permeabilized, and stained for FOXP3 using the FOXP3 
Fix/Perm Buffer Set according to the manufacturer’s protocol 
(BioLegend).
For analysis of intracellular cytokine production, T cells were 
restimulated on day 5 with 16.2 nM PMA and 1 µM ionomycin 
for 6 h with addition of 1 µM monensin for the last 4 h. The cells 
were fixed with 4% paraformaldehyde and permeabilized in 0.1% 
saponin (both from Sigma-Aldrich) in PBS. Before adding anti-
IFNγ and anti-IL-17A mAbs, cells were blocked with 2.4 mg/ml 
human IgG (Beriglobin P) diluted in the intracellular staining 
buffer (5% FCS, 0.1% saponin in PBS) that was also used for 
washing.
gene expression analysis
Total RNA was extracted with the PureLink RNA Mini Kit 
(Ambion, Austin, TX, USA) or TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) supplemented with β-mercaptoethanol for 
RNAse inhibition. cDNA synthesis, quantitative PCR using GoTaq 
qPCR Master Mix (Promega, Madison, WI, USA) and analysis was 
performed as previously described (23). Primers are listed in Table 
S1 in Supplementary Material. ACTB was used as endogenous 
control unless stated otherwise and results are reported relative to 
values for one of the samples as specified in figure legends.
For microarray analysis, RNA was isolated from the different 
Mϕ subsets using PureLink RNA Mini Kit (Ambion). 500 ng of 
total RNA from each sample (in biological triplicates) was used 
for amplification, labeling, and hybridization using GeneChip 
Primeview Human Gene Expression Array and 3′IVT Express 
Kit Bundle (Affymetrix, Santa Clara, CA, USA). RMA was used 
for normalization of the dataset (24) and further analysis was 
done with limma (25).
The microarray data were submitted to the GEO repository 
(accession No. GSE61298).
Heat maps for specific genes were created using TM4 (26) using 
probe sets with expression above the threshold values (log2 > 5) in 
at least one sample. If a gene contained duplicate probe sets, their 
mean value was calculated and loaded into TM4. For Figure 1C, the 
threshold was increased to log2 = 7 and probe sets with differential 
expression upon activation or upon differentiation, respectively, 
were used (adj. p value < 0.05) and averaged before loading into 
TM4 to visualize differentially expressed genes with moderate to 
high expression only. Hierarchical clustering was done by TM4 
based on Pearson correlation as the distance metrics.
cytokine Measurements
IL-1β, TNF-α, IL-6, IL-12 (p40, p70), IL-23, IL-10, vascular 
endothelial growth factor (VEGF), IL-2, IL-4, and IFNγ were 
measured from cell-free supernatants by Luminex analysis as 
detailed previously (23). Active TGF-β was determined using the 
SERPINE1 (PAI-1) promoter-driven luciferase reporter assay (27).
extracellular aTP Degradation and 
adenosine Measurements
Human Mϕ subtypes were differentiated and activated as described 
above. Mϕ-mediated degradation of 20 µM ATP in serum-free 
RPMI 1640 medium was monitored after 30 min at 37°C from 
cell-free supernatants using the Luminescent ATP detection Assay 
kit (Abcam, Cambridge, UK), omitting lysis step. For normaliza-
tion, cells were lysed separately and the total protein amount was 
detected by Bradford protein assay (Bio-Rad, Hercules, CA, USA).
Adenosine was determined from the cell-free culture media 
of 7 days-differentiated and 2 days (48 h)-activated Mϕ cultures 
by liquid chromatography/mass spectrometry (LC/MS). For that, 
100 µl of cell culture medium was spiked in with 1 µg deuterated 
adenosine as the internal standard and samples were deproteinated 
by chloroform–methanol extraction and lyophylized. The sample 
extract was dissolved in eluent (75% acetonitrile/100 mM aque-
ous ammonium acetate, pH 4.5) and 2 µl were injected onto the 
separation column (SeQuant® ZIC®-cHILIC 100 mm × 0.3 mm, 
which was kindly provided by Merck, Darmstadt, Germany). 
Adenosine was separated using isocratic separation conditions on 
the Dionex nano RSLC HPLC (Thermo Fisher Scientific) system. 
The column was operated at 45°C using a flow rate of 8 µl/min. 
UV detection was performed at 260 nm prior to ESI-MS operated 
in positive ionization mode using a Bruker maXis Impact mass 
spectrometer (Bruker, Bremen, Germany). The MRM scan of 
the transition m/z 268.097 (MH+) to m/z 136.054 (MH+) was 
performed using the CID-MS/MS. The peak area of extracted ion 
chromatograms for m/z 268.097 were integrated using Data-
Analysis Version 4.1 (Bruker Daltonik, Bremen, Germany). The 
resulting peak area was corrected using the area of the internal 
standard with m/z 269.103 (MH+); MRM transition 269.103 
to 137.053. Finally, adenosine concentration in the samples was 
calculated from the adenosine calibration curve ranging from 0 
to 10 µg/ml cold adenosine spiked in with the internal standard 
and processed as described above.
live cell imaging
Human Mϕs differentiated with M-CSF for 7  days were acti-
vated with 100 ng/ml LPS plus 25 ng/ml IFNγ on low-adherent 
HydroCell plates (NUNC, Thermo Fisher Scientific) for 2 days, 
then detached using ice-cold 1.5 mM EDTA in HBSS (Gibco), 
washed with PBS supplemented with 10% FCS, and loaded with 
CD3 mAb OKT3 (50 µg/ml) for 30 min on ice. Then, Mϕs were 
stained with Brilliant Violet 421-labeled CD39 and PE-labeled 
CD73 mAbs (or labeled isotype-matched control mAbs) for 
30  min on ice and washed twice with PBS supplemented with 
10% FCS. One day prior to imaging, autologous CD4+ T  cells 
were defrosted and left to recover overnight. In some experi-
ments, on the day of imaging, living T  cells were purified by 
gradient centrifugation using Lymphoprep (Axis-Shield, Oslo, 
Norway) and extensively washed with PBS. CD4+ T cells (106/ml) 
were loaded with 1 µM Fluo-4 in complete culture medium for 
30 min at 25°C and then washed twice with the imaging buffer 
[HBSS supplemented with 2% FCS, 10  mM HEPES pH 7.4 
(Gibco), 1 mM MgCl2, and 1 mM CaCl2]. For imaging, first the 
Mϕs, then T cells were put onto a 1.0 borosilicate glass surface 
of an 8-well Lab-Tek II chamber slide (NUNC) at 25°C. Image 
acquisition was performed with a Leica DMI4000B microscope 
(Leica Microsystems; Wetzlar, Germany) equipped with a 40× 
immersion objective (Leica HCX PL Apo 40×, NA 1.25) and an 
Andor iXon Ultra-8871 EM-CCD camera (Andor Technologies; 
FigUre 1 | Activated human GM-CSF- and M-CSF-differentiated macrophage (Mϕ) subtypes are distinguishable by their surface marker, cytokine, and chemokine 
profiles. Human Mϕs were differentiated for 7 days with either GM-CSF or M-CSF and then activated for 2 days with the indicated stimuli. (a) Surface expression of 
Mϕ markers was measured by flow cytometry. Mock-activated cells are shown in black, cells activated with—LPS + IFNγ in red, with IL-4 in blue and with IL-10 in 
green. Control staining of mock-activated cells using the isotype control monoclonal antibodies is shown in gray (isotype control staining of activated cells was 
similar and is not depicted here). One representative of 10–12 experiments is shown. (B) Genome-wide analysis of Mϕ polarization was assessed by transcriptome 
profiling of Mϕ subtypes from (a). Hierarchical clustering of Mϕ subtypes based on 22,067 gene probe sets (≈44.7%) that showed a significantly different 
expression (adj. p value <0.05) in at least one comparison. Data are combined from three independent experiments. (c) Heat map of transcripts of cytokine and 
chemokine genes based on the differentially expressed gene probe sets (115 gene probe sets; adj. p value < 0.05) with log2 expression > 7 in at least one sample. 
Important gene clusters discussed (I–V) are highlighted on the right. Mϕs have been generated from three donors and are visualized separately. (D) Active TGF-β 
from cell-free culture supernatants was determined using the SERPINE1 (PAI-1) promoter-driven luciferase reporter assay, while the other cytokines were measured 
by the Luminex analysis. The mean cytokine concentration ± SEM from 5 to 6 donors is shown. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical significance was 
determined by one-way ANOVA with Tukey’s posttest. The hash key (#) indicates that the IL-10 levels in the IL-10-stimulated Mϕ subtype represent a mixture of 
released and residual IL-10 from the activation step and, therefore, were not evaluated.
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Belfast, UK) controlled by the Leica Application Suite Advanced 
Fluorescence software (version AF6000LX). Imaging of Fluo-4, 
PE and Brilliant Violet 421 excitation and emission light filtering 
was achieved through the Leica Quad-Sedat filter system (dichroic: 
430,505,757,670) including two external filter wheels DFTC-Ex 
(350/50, 490/20, 555/26, 645/30) and DFTC-Em (455/50, 525/36, 
605/52, 705/72). DIC and fluorescence images were collected at 
intervals of 1 min over 45–50 min. Synapse formation and T cell 
intracellular calcium dynamics determined by monitoring of the 
Fluo-4 fluorescence were analyzed with the open source image 
analysis software package Fiji (28).
human serum albumin (hsa) coupling to 
methotrexate (MTX) and Folic acid (Fa)
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
(EDAC) and N-hydroxysuccinimide (both from Sigma-Aldrich) 
were dissolved independently in dimethyl sulfoxide (DMSO) and 
mixed with MTX dissolved also in DMSO. The solution was kept 
under continuous stirring in a glass labware until complete dis-
solution. Activation was performed at 50°C in a water bath during 
15 min. Activated MTX was then added drop by drop to HSA 
dissolved in 130 mM NaHCO3 buffer, pH 7.2 under continuous 
stirring at room temperature (RT) and the final solution incu-
bated for a 20-min period at RT. Conjugation was followed by 
extensive dialysis against NaHCO3 buffer (membrane cut-off of 
20 kDa) to eliminate free MTX. HSA and MTX concentrations 
were determined by measuring the optical density of the solution 
at 280 and 370 nm, respectively.
The same protocol was used to activate FA. Half of the HSA-
MTX solution was then mixed with activated FA at RT under 
continuous stirring, followed by 20-min incubation at RT. The 
molecular ratio between HSA, MTX, and FA was calculated to be 
1:1.6:1.2 by measuring absorbance of the different conjugates at 
280 (for HSA) and 370 nm (for MTX and FA). All solutions were 
dialyzed against PBS and filter sterilized before use.
collagen-induced arthritis (cia) Mouse 
Model and Ex Vivo analysis of Mϕs by 
Flow cytometry
6-week-old DBA/1JRj male mice were purchased from Janvier 
Laboratory (Le Genest-St.-Isle, France). Arthritis was induced 
with type II bovine collagen (CII; MD Bioscience, Zurich, 
Switzerland) as previously described in Ref. (29). Briefly, mice 
were injected intradermally at the base of the tail with 100 µg of 
CII emulsified in Freund’s adjuvant (BD DIFCO, Thermo Fisher 
Scientific). On day 21, mice were boosted with an intradermal 
injection of CII in incomplete Freund’s adjuvant (BD DIFCO, 
Thermo Fisher Scientific). Mice were monitored for evidence 
of arthritis in paws using a blind procedure. For each mouse, 
clinical severity of arthritis was scored (0-normal; 1-erythema; 
2-swelling; 3-deformity; 4-necrosis) in 10 joints or group of joints 
(toes, tarsus, ankle of the hindleg and fingers, and carpus of the 
foreleg) as detailed elsewhere (29). The MTX (35  mg/kg; the 
HSA conjugates were used at the amount equivalent to 7 mg/kg 
of free MTX) and the vehicle control (PBS) treatments injected 
were randomized in each cage to avoid cage dependence of the 
clinical score. Treatment started 14 days after immunization, with 
intraperitoneal injections twice a week, and mice were scored the 
same day.
For flow cytometry analysis, ankles were dissected, digested 
with collagenase (50 µg/ml) diluted in RPMI 1640 medium without 
serum for 2 h at 37°C. Then, ankles were dissociated and the cell 
suspension was filtered through a 40 µm cell strainer. For surface 
staining, Fc receptors were blocked with normal goat and rabbit 
IgG (10 µg/ml) in PBS with 1% BSA for 30 min on ice. Cells were 
then stained in the same medium with an anti-murine FRβ for 
30 min on ice, washed with PBS with 1% BSA and incubated with 
a Dylight 488-conjugated anti-rat secondary Ab (eBioscience) for 
30 min on ice. After two consecutive washes, cells were stained 
with rat anti-mouse-CD11b, F4/80, CD39, and CD73 for 30 min 
on ice, washed again, and measured using an LSR II flow cytom-
eter (BD Biosciences) equipped with the FACSDiva software; and 
the data were further processed with the FlowJo software.
The experiments using mouse models were approved by the 
French Ministry of Research and the Paris Descartes University 
Ethical Committee (CEEA N°34); agreement N°CEEA34.GB.029.11. 
All methods and experiments were performed in accordance with 
the relevant guidelines and regulations.
statistics
The number of independent experiments (human donors) and mice 
in animal studies is specified in the figure legends. The statisti-
cal significance between subsets of the particular Mϕ lineages 
was assessed as specified in the figure legends using Prism 5 
(GraphPad Software, La Jolla, CA, USA). Additionally, for assess-
ment of the difference between the samples activated with the 
same stimuli two-tailed unpaired t-test was used. In all analyses, 
statistical significance was accepted at p < 0.05.
resUlTs
M-csF-Dependent Mϕs show a  
skewed M1/M2 Profile in response  
to M1 activation stimuli
To establish a model system for RA-associated Mϕs, we dif-
ferentiated human CD14hi monocytes into Mϕs by culturing 
them for 7 days with either GM-CSF or M-CSF, which are both 
upregulated in RA tissues (12). Mϕs were then treated with 
LPS + IFNγ for 48 h to mimic chronic inflammatory conditions 
(M1 state). Alternatively, we used IL-4 or IL-10 (the latter for the 
M-CSF-primed Mϕs only) to activate Mϕs to the M2/M2-like 
states (20). We confirmed the activation states by assessing 
surface expression of several Mϕ markers by flow cytometry 
(Figure  1A; Figure S1 in Supplementary Material that can be 
found with all other Supplementary Figures in Supplementary 
Material). GM-CSF-differentiated Mϕs were characterized by 
lower expression of the LPS coreceptor CD14 than M-CSF-
differentiated Mϕs, while CD64 was strongly expressed by mock- 
activated GM-CSF-differentiated Mϕs. Both markers were highly 
expressed by LPS + IFNγ- and IL-10-stimulated Mϕs and strongly 
downregulated in response to IL-4. The commonly used M2 
marker CD206 (5), was not found specific for M2 Mϕs, since it 
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was highly expressed by all subtypes, though further upregulated 
by IL-4. In contrast, the M2 marker FRβ (3) was expressed at high 
levels exclusively by the M-CSF lineage regardless of subsequent 
polarization. Other M2 markers CD163 and CD209 were also 
preferentially expressed on M-CSF-differentiated Mϕs, but in 
contrast to FRβ, expression of these markers varied, depending on 
the activation stimulus: CD163 expression was the highest in the 
presence of IL-10, while CD209 was upregulated in response to 
IL-4 in both lineages. Thus, by probing for these Mϕ markers, we 
are able to discriminate GM-CSF- versus M-CSF-differentiated 
Mϕs and assess their activation status. These data also reveal that 
M-CSF-dependent Mϕs express certain M2 markers even in the 
proinflammatory environment.
To gain a better insight into Mϕ polarization, we analyzed 
the transcriptome of these seven subtypes using a whole-human 
genome microarray. On the transcriptome-wide level, Mϕs clus- 
tered according to the activation regime, with LPS +  IFNγ-
activated Mϕs of both lineages in one branch and IL-4-activated 
Mϕs segregating at the furthest end of the other branch (Figure 1B). 
Similar results we obtained when we focused onto analysis of 
genes encoding cytokines and chemokines, which are both crucial 
effector molecules and markers of different Mϕ types (Figure 1C). 
IL-4-activated Mϕs of both lineages highly expressed a cluster of 
M2-associated chemokine genes (cluster I; CCL13, CCL17, CCL22, 
CCL24, CCL26). Again, the most pronounced changes were caused 
by LPS + IFNγ stimulation. Here, we detected a robust upregulation 
of genes encoding proinflammatory cytokines and chemokines. 
Nevertheless, a subgroup of them (clusters II–IV) was expressed 
at lower levels in the M-CSF-differentiated LPS + IFNγ subtype: 
while the genes in cluster II (TNF and CXCL2) and III (IL1A, IL6, 
IL23A, CXCL1-CXCL3, and CCL20) were found to be uniformly 
upregulated to some extent, several genes from cluster IV (CSF2, 
CXCL6, and IL1F9) were mildly upregulated only in one donor. 
Furthermore, this Mϕ subtype barely upregulated IL12B, encod-
ing the p40 subunit of IL-12/IL-23, IL18, and CCL1 (cluster V), 
but expressed IL10.
To confirm the transcriptome data, we measured the cytokines 
in the culture supernatants of the activated Mϕs (Figure  1D). 
LPS  +  IFNγ-stimulated Mϕs of both lineages released high 
amounts of proinflammatory cytokines TNF-α, IL-1β, and IL-6 
and immunoregulatory TGF-β. These cytokines were slightly better 
produced by the GM-CSF-dependent subtype. However, the two 
cell types showed clear differences in secretion of the Th1- and Th17-
instructing cytokines IL-12 and IL-23: GM-CSF-differentiated 
Mϕs scored highly positive, while those differentiated by M-CSF 
did not; instead, they produced high levels of IL-10 and VEGF.
Taken together, these results reveal a distinct response of 
GM-CSF- and M-CSF-differentiated Mϕs to LPS + IFNγ stim-
ulation that is not apparent on transcriptome-wide level, and 
indicate that M-CSF-differentiated/LPS + IFNγ-stimulated Mϕs 
with the M1/M2 profile might be less inflammatory.
M1-stimulated M-csF-Dependent Mϕs 
inhibit T cell responses
Next, we probed for Mϕ ability to stimulate T cells. In coculture 
experiments with CFSE-labeled autologous CD4+ T cells, no Mϕ 
subtype activated T  cells without ectopic T  cell antigen receptor 
(TCR) triggering, as revealed by co-staining of the T cell activation 
markers CD69 and CD147 on day 2. But in the presence of soluble 
CD3 mAb, all subtypes were able to provide T cells with the necessary 
second stimulus (Figure 2A). Yet, the degree of T cell activation var-
ied, with the lowest percentage of activated (CD69+CD147hi) T cells 
when cocultivated with the M-CSF-differentiated/LPS  +  IFNγ-
stimulated Mϕs (Figures 2A,B). We found that this was due to the 
impaired upregulation of the late activation marker CD147 (30), while 
robustly upregulated CD69 (an early activation marker) and CD25 
(an intermediate activation marker) (31) were not significantly 
affected (Figure S2A in Supplementary Material). T cells cocultured 
with M-CSF-differentiated/LPS +  IFNγ-stimulated Mϕs also 
released lower amounts of IL-2, IFNγ, IL-4, and IL-10 compared 
to the other samples (Figure S2B in Supplementary Material). 
Hyporeactivity of these T cells was also detectable, when proximal 
TCR signaling was bypassed by restimulation with the mitogen PMA 
and the calcium ionophore ionomycin, as revealed by intracellular 
staining of IFNγ and IL-17A on day 5 (Figures 2C,D). In contrast, 
when cocultured with similarly activated GM-CSF-differentiated 
Mϕs, T cells released high levels of all cytokines measured (Figure 
S2B in Supplementary Material) and contained the highest fre-
quency of IFNγ- and IL-17A-producing cells (Figures 2C,D).
Finally, we monitored T cell proliferation by quantitating CFSE 
dilution 7 days after coculture. As shown in Figure 2E, no Mϕ 
subtype was able to markedly induce T cell proliferation under 
control conditions. CD3 mAb-stimulated T cells cultured alone 
were found anergic, likely due to missing CD28-mediated co- 
stimulation, while high T  cell proliferation was detected in 
cocultures with all types of GM-CSF-differentiated Mϕs and 
M-CSF-differentiated/IL-4-activated Mϕs (Figures 2E,F). In con-
trast, T cells cocultured with M-CSF-differentiated/LPS + IFNγ-
activated Mϕs proliferated markedly less (Figures  2E,F). A 
time-course analysis showed that they practically stopped divi ding 
between days 5 and 7 (Figure S2C in Supplementary Material). 
Based on these data, we speculated that a combination of M-CSF 
and proinflammatory stimuli drives Mϕs toward the immuno-
suppressive phenotype.
Mechanisms of T cell suppression 
Mediated by the immunoregulatory  
Mϕ subtype
To uncover the mechanism underlying this immunosuppressive 
phenotype, we tested induction of FOXP3+CD4+CD25+ regula-
tory T cells (Tregs). In control cocultures, the FOXP3+ cells were 
probably natural Tregs. As reported (32), FOXP3 expression 
moderately increased upon T cell activation. Lowest levels were 
detected in coculture with M-CSF-differentiated/LPS +  IFNγ-
stimulated Mϕs, revealing that they did not induce Treg differen-
tiation (Figures S3A,B in Supplementary Material).
We, therefore, searched for cell-intrinsic mechanisms of immu-
noregulation. First, we checked antigen-presenting and costimu-
latory molecules. In agreement with the results of coculture 
assays, the potent stimulators (GM-CSF-differentiated Mϕs 
activated with LPS +  IFNγ or IL-4) expressed highest levels of 
MHC class II and the costimulatory receptors CD80, CD86, 
CD40 and, in some donors, also the (glyco)lipid-presenting 
FigUre 2 | M-CSF-differentiated macrophages (Mϕs) activated with LPS + IFNγ suppress activation, cytokine production, and proliferation of autologous CD4+ 
T cells. Mϕs described in Figure 1 were cocultured with CFSE-labeled autologous CD4+ T cells in the presence or absence of the stimulating CD3 monoclonal 
antibody (mAb) OKT3. As a control, T cells were cultured alone as indicated. (a,B) CD4+ T cells were stained for activation markers CD69 and CD147 after  
2 days coculture with different Mϕ subtypes. The percentage of activated cells is given in the CD69+CD147hi gate. One representative experiment (a) and statistics 
(B) of eight independent experiments is shown. (c,D) Mϕ subtypes were cocultured with unlabeled autologous CD4+ T cells in the presence of the CD3 mAb. After 
5 days of coculture, T cells were restimulated with phorbol 12-myristate 13-acetate and ionomycin for 6 h and stained for IFNγ and IL-17A. One representative 
experiment (c) and the mean percentages (representing the sum of the respective single and double-positive gates) ± SEM (D) of the IFNγ- and IL-17A-expressing 
T cells of seven independent experiments are shown. (e) Proliferation of CFSE-labeled T cells cocultured with autologous Mϕs ± CD3 mAb was determined by 
CFSE dilution on day 7 using flow cytometry. One representative experiment, where CFSEhi non-dividing cells are gated, of nine independent experiments is shown. 
(F) T cell division index was calculated according to the CFSE peaks. Data represent means ± SEM of nine independent experiments. Expression of activation 
markers (B), cytokines (D), and proliferation (F) of the CD3-stimulated T cells in Mϕ cocultures were statistically evaluated by one-way ANOVA with Tukey’s posttest; 
*p < 0.05, **p < 0.01, ***p < 0.001.
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molecule CD1a. The immunosuppressive M-CSF-differentiated/
LPS +  IFNγ-stimulated Mϕs expressed high levels of MHCII, 
CD80, CD40, but not CD86 (Figures S3C,D in Supplementary 
Material). Nevertheless, since other M-CSF-differentiated T cell-
stimulating subtypes expressed even lower levels of costimulatory 
molecules (Figures S3C,D in Supplementary Material) and M-CSF- 
differentiated/LPS + IFNγ-activated Mϕs suppressed T cell pro-
liferation even in the presence of CD3 + CD28 mAbs (Figures 
S2D,E in Supplementary Material), we excluded missing co-
stimulation as a possible mechanism.
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Second, based on our microarray data we compared expression 
of genes, which were differentially regulated in response to 
LPS +  IFNγ in GM-CSF- versus M-CSF-differentiated Mϕs. We 
focused on genes involved in T cell stimulation or inhibition (33). 
This analysis corroborated preferential upregulation of genes 
encoding proinflammatory cytokines (IL12B, TNF, IL6) and 
costimulatory molecules (red highlighted in Figure S3E in Supp-
lementary Material) by GM-CSF-primed Mϕs, while both Mϕ 
lineages upregulated several genes associated with T cell inhibition 
or immunoregulation: IL10, CD274 (PD-L1), PDCD1LG2 (PD-L2), 
IDO1, IDO2, IL2RA (CD25), and SOCS1-SOCS3 (blue and green 
highlighted in Figure S3E in Supplementary Material). In subse-
quent staining experiments, we confirmed that PD-L1, which 
inhibits T cells by engaging PD-1 (33), and CD25, which scavenges 
IL-2 from T cells (34), were uniquely upregulated by LPS + IFNγ 
(Figure S3F in Supplementary Material). Since their surface 
expression varied minimally between the T  cell-stimulating and 
T cell-inhibitory subset, they were unlikely to mediate T cell sup-
pression. Similarly, we also excluded IL-10 as a sole mediator of the 
suppressor phenotype, as the blocking IL-10 mAb did not restore 
T cell proliferation in coculture experiments (data not shown).
Mϕs alter extracellular Purine Metabolism 
in response to Proinflammatory stimuli
Our search for LPS +  IFNγ-regulated genes involved in T  cell 
suppression revealed altered expression of several genes involved 
in adenosine metabolism and signaling (NT5E, coding for the 
ecto-5′-nucleotidase CD73, and adenosine receptors ADORA2A, 
ADORA2B; Figure S3E in Supplementary Material). Extracellular 
adenosine generated from ATP released by activated T cells was 
found to potently suppress T cell functions (34, 35). The canoni-
cal pathway responsible for conversion of extracellular ATP to 
adenosine (Figure S4A in Supplementary Material) is represented 
by ectonucleotidases CD39 (ENTPD1) and CD73 (36, 37). We, 
therefore, measured surface expression of these enzymes on Mϕs 
by flow cytometry. All types of M-CSF-differentiated Mϕs expre-
ssed high levels of surface CD39; GM-CSF-differentiated Mϕs 
scored also positively but to a lesser extent (Figures 3A,B) and 
exhibited a lower capacity to degrade exogenous ATP (Figure 3C). 
CD73 was specifically upregulated in LPS + IFNγ-activated Mϕs 
secreting high amounts of TGF-β, IL-1β, and TNF-α (Figure 1D), 
which were shown to induce CD73 in non-Mϕ cells (38, 39). 
Remarkably, on the surface of the immunostimulatory GM-CSF-
differentiated Mϕs, CD39 and CD73 appeared in two different 
subpopulations in a mutually exclusive manner. In contrast, 
M-CSF-differentiated Mϕs contained a prominent CD39+CD73+ 
double-positive subpopulation (Figures 3A,B).
Cohen et al. reported that mouse Mϕs release ATP in response 
to TLR stimulation through pannexin-1 (Panx1) channels (40). 
In line with these data, we detected profound upregulation of the 
PANX1 and GJB2 transcripts, which code for the ATP-releasing 
channels Panx1 and connexin-26 in the immunosuppressive 
Mϕs (Figure 3D). Other ATP-releasing channels, P2X and P2Y 
nucleotide receptors were expressed similarly by several sub-
types (Figure S4B in Supplementary Material). To test whether 
M-CSF- and LPS + IFNγ-stimulated Mϕs indeed produce adeno-
sine in a Panx1/connexin-26/CD39/CD73-dependent manner, 
we measured extracellular adenosine in Mϕ culture media. We 
dete cted the highest levels of adenosine in supernatants of 
M-CSF-differentiated Mϕs activated with the M1 stimuli, but 
these differences were not significant (Figure 3E). Therefore, we 
assessed the expression of adenosine-binding and -degrading 
proteins (Figures 3F–H; Figure S4B in Supplementary Material). 
Adenosine receptor transcripts, encoded by the ADORA genes, 
intensely fluctuated (Figure  3F): ADORA1 mRNA levels were 
minimal and together with ADORA2B transcripts, they decreased 
upon Mϕ activation, while ADORA3 was predominantly expre-
ssed in the M-CSF lineage with exception of the LPS +  IFNγ-
stimulated subset. The most prominent change was detected in 
ADORA2A transcripts upon LPS + IFNγ treatment that increased 
most in the immunosuppressive M-CSF-differentiated subtype. 
Notably, this subtype expressed the lowest amounts of other 
adenosine receptors and adenosine reuptake channels SLC28A3 
and SLC29A3 (Figure 3G); however, it expressed high levels of 
adenosine-catabolizing adenosine deaminase (Figure 3H). Taken 
together, these data indicate that proinflammatory stimuli affect 
gene expression of the purinergic pathway in Mϕs. Further, they 
suggest that extracellular adenosine production and signaling is 
more efficient in the M-CSF than in the GM-CSF lineage.
The Mϕ Purinergic Pathway Dynamically 
responds to changes in extracellular 
nucleotides
In order to assess the functionality of the purinergic pathway in 
LPS  +  IFNγ-stimulated Mϕs, we blocked the prime enzyme 
CD39 with the small molecule inhibitor POM-1 during the 2-day 
activation step. We observed that the CD39 blockade suppressed 
the LPS  +  IFNγ-upregulated expression of PANX1 and GJB2 
transcripts, encoding the ATP-releasing channels (Figure  4A). 
The POM-1 treatment further increased the LPS + IFNγ-induced 
expression of CD73 in the T cell activating (GM-CSF-differentiated) 
and especially in the immunosuppressive (M-CSF-differentiated) 
subtype, enhancing the CD39+CD73+ subpopulation, while no such 
effect was observed in the other Mϕ subtypes (Figures 4B,C). POM-
1-mediated upregulation of CD73 in LPS  +  IFNγ-treated Mϕs 
was likely caused by accumulated extracellular ATP resulting from 
CD39 inhibition, because exogenously added ATP was also able to 
increase CD73 expression, although significance was reached only 
in the M-CSF-dependent subset (Figures  4D,E). Based on these 
results, we speculated that CD73 expression could be also modu-
lated by extracellular adenosine in a negative feedback loop. Indeed, 
we observed a trend toward the reduction of CD73 expression on 
the surface of both LPS + IFNγ-stimulated Mϕs that were treated 
exogenously with adenosine (Figures 4F,G). Taken together, these 
data suggest that the expression of several genes of the purinergic 
pathway in Mϕs is modulated by extracellular ATP and its degrada-
tion products to ensure optimal functionality of the pathway.
Mϕs enrich cD39 Within the 
immunological synapse to attenuate  
T cell activation
In response to TCR stimulation, T cells release ATP into the immu-
nological synapse that significantly contributes to localized calcium 
FigUre 3 | Expression and function of genes of the purinergic pathway upon LPS + IFNγ treatment of M-CSF- or GM-CSF-differentiated macrophages (Mϕs). 
Human Mϕ subtypes were prepared as described in Figure 1. (a,B) Surface expression of AMP- and adenosine-producing enzymes CD39 and CD73 on different 
Mϕ subsets was determined by flow cytometry. One representative experiment (a) and the mean percentages (±SEM) of CD39+CD73+ cells from five experiments 
are shown (B). (c) Degradation of 20 µM ATP by Mϕ subtypes. After 30 min, remaining ATP was measured and normalized to the Mϕ protein content. (D) mRNA 
expression of genes encoding ATP-releasing channels pannexin 1 (PANX1) and connexin 26 (GJB2) was analyzed by qRT-PCR. (e) Adenosine was measured in  
the cell-free culture supernatants by mass spectrometry. (F–h) mRNA expression of genes encoding (F) adenosine receptors (ADORA1-3), (g) adenosine uptake 
channels (SLC28A3, SLC29A3) and (h) the adenosine-catabolizing enzyme adenosine deaminase (ADA) was analyzed by qRT-PCR. To compare the expression  
of the various adenosine receptors, we normalized the data to ADORA1 mRNA levels in GM-CSF control Mϕs that were set to one. Other genes were normalized  
to the respective levels found in GM-CSF control Mϕs that were set to one (D,g,h). Data in (c–h) represent mean values ± SEM of three (c,D,g,h) to five  
(e,F) donors. Statistical significance was assessed by one-way ANOVA with Tukey’s posttest; *p < 0.05, **p < 0.01, ***p < 0.001.
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FigUre 4 | Effects of the CD39 inhibitor POM-1, extracellular ATP, and extracellular adenosine on expression of ATP release channels and adenosine-producing 
enzymes. (a) Macrophages (Mϕs) of both lineages were activated for 2 days with LPS + IFNγ in the absence (control) or presence of 20 µM POM-1. Expression of 
the genes encoding ATP release channels PANX1 and GJB2 was then analyzed by qRT-PCR. To compare gene expression, the data were normalized to the mRNA 
levels in the M-CSF LPS + IFNγ-stimulated Mϕs that were set to one. Data represent five different donors. (B–g) Mϕs were differentiated and activated as indicated. 
POM-1, ATP, adenosine, or respective controls were added during the activation step. (B) The expression of CD39 and CD73 on the indicated Mϕ subtypes in the 
absence or presence of 20 µM POM-1 was analyzed by flow cytometry. (c) Quantification of the data shown in (B) (n = 12). (D,e) Expression of CD39 and CD73  
on GM-CSF or M-CSF-differentiated Mϕs in the absence or presence of 100 µM ATP was analyzed by flow cytometry. One representative experiment (D) and 
statistics from four independent experiments (e) is given. (F,g) Flow cytometry analysis of CD39 and CD73 expression on the surface of LPS + IFNγ-stimulated  
GM-CSF- or M-CSF-differentiated Mϕs in the absence or presence of 10 µM adenosine. One representative experiment (F) and statistics from four independent 
experiments (g) is given. Statistical significance was assessed by unpaired two-tailed t-test or one sample t-test for GM-CSF- or M-CSF-differentiated Mϕs, 
respectively (a) or by two-way ANOVA with Bonferroni posttest (c,e,g); *p < 0.05, **p < 0.01, ***p < 0.001.
11
Ohradanova-Repic et al. Adenosine-Mediated Switch of M-CSF-Dependent M1 Mϕs
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 852
entry by the P2X1 and P2X4 ATP-gated calcium channels and 
T cell activation (41). To scrutinize whether T cell-derived ATP, 
converted to adenosine by Mϕ ectonucleotidases, contributes to 
immunosupression, we analyzed the first minutes of the CD3 mAb-
mediated interaction between M-CSF-differentiated/LPS + IFNγ-
activated Mϕs and CD4+ T cells by live cell video microscopy. 
FigUre 5 | Continued
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CD39+CD73+, CD39+CD73− and the seldomly observed CD39− 
CD73+ Mϕs exhibited lower capacity to engage T cells into an 
active immunological synapse than their CD39−CD73−counter-
parts (Figure  5A). Nevertheless, early T  cell sign aling was not 
blocked by the CD39+CD73+ Mϕs, since T  cells increased 
intracellular calcium when they eventually got engaged. This 
prompted us to analyze the expression of the adenosine receptors 
in T cells. In line with the published data (42, 43), we found that 
the ADORA2A and ADORA2B transcripts gradually increased 
during T cell activation until day 3 (Figure S5 in Supplementary 
Material).
Of note, we observed that in ≈26% synapses of CD39+ Mϕs, 
CD39 staining was more intense than in areas outside of the 
synapse (Figures  5B,C), while CD73 was rarely enriched in 
these synapses. Furthermore, the recruitment of Mϕ CD39 
into the immunological synapse was associated with a more 
rapid decrease of intracellular calcium flux in engaged T  cells 
(Figures 5C–E; Movies S1 and S2 in Supplementary Material). 
These observations point to an essential role of Mϕ CD39 in 
modulating early phases of T cell activation. The CD39/CD73-
generated adenosine did not seem to be crucial at this stage, pos-
sibly due to the low expression of adenosine receptors on resting 
and recently activated T  cells (Figure S5 in Supplementary 
Material).
cD39 Blockade abrogates Mϕ 
immunosuppressive Functions
Extracellular adenosine is well-known to dampen proinflamma-
tory responses of immune cells, including Mϕs (35, 37, 44). To 
scrutinize the autocrine effects of adenosine generated from ATP 
by the Panx1/connexin-26/CD39/CD73-dependent mechanism 
in the immunoregulatory Mϕs, we treated Mϕs of both lineages 
with LPS + IFNγ and the CD39 inhibitor POM-1. After 2 days, 
we examined the expression of cytokine genes. Upon POM-1 
treatment, we observed a more proinflammatory phenotype in 
the immunosuppressive M-CSF-differentiated subtype with enha-
nced IL6, IL12B, and IL23A expression. Further, IL10 expression 
was reduced in three donors (Figure  6A). On the other hand, 
the highly expressed IL6 and IL23A genes in the GM-CSF-
differentiated subtype were rather downregulated by POM-1. 
Surprisingly, the highly expressed TNF was mildly downregulated 
in both Mϕ subtypes.
To further inspect the functional consequence of the CD39 
blockade, we cocultured control and POM-1-pretreated Mϕs with 
autologous CD4+ T  cells. POM-1 pretreatment of the M-CSF-
differentiated/LPS + IFNγ-stimulated Mϕs abrogated their T cell- 
suppressive function, resulting in enhanced expression of the 
intermediate and late activation markers CD25 and CD147 on day 
2 (Figure 6B), increased frequency of cytokine-producing T cells 
on day 5 (Figure 6C), and substantially enhanced T cell prolifera-
tion on day 7 (Figures 6D–F). In contrast, T cells cocultured with 
similarly treated GM-CSF-differentiated Mϕs produced lower 
amounts of IL-17A than T cells cocultured with Mϕs that were 
not treated with the CD39 inhibitor (Figure 6C). This correlated 
with POM-1-mediated changes of the IL6 mRNA expression in 
the GM-CSF- and LPS + IFNγ-stimulated Mϕs (Figure 6A). Yet, 
the POM-1 pretreatment of this subtype had only minor effect 
on subsequent T cell proliferation, while pretreatment of all other 
Mϕ subtypes did not significantly affect T cells (Figures 6D–F). 
Thus, these data demonstrate that in response to the proinflam-
matory stimuli, M-CSF-differentiated Mϕs produce adenosine 
that skews them toward the immunoregulatory subtype, leading 
to T  cell inhibition. In contrast, adenosine production by the 
GM-CSF-dependent Mϕs rather seems to potentiate their proin-
flammatory properties.
FigUre 5 | CD39 on M-CSF-differentiated and LPS + IFNγ-activated 
macrophages (Mϕs) influences the frequency of the synapse formation  
and the quality of the calcium response of engaged CD4+ T cells. Human 
Mϕs were differentiated for 7 days with M-CSF and then activated for 2 days 
with LPS + IFNγ. Afterward, they were loaded with CD3 monoclonal antibody 
(mAb), stained with PE-conjugated CD73- and Brilliant Violet 421-conjugated 
CD39 mAbs, and incubated with Fluo-4-loaded autologous CD4+ T cells. 
Time-lapse microscopy images were acquired every minute for 45–55 min. 
(a) The average numbers of T cells engaged in the synapse and T cells that 
touched CD39+CD73+, CD39+CD73−, CD39−CD73+, or CD39−CD73− Mϕs 
were counted. Data are mean ± SEM of three experiments. Statistical 
significance was assessed by one-way ANOVA with Tukey’s posttest; 
*p < 0.05. (B) Mean percentage of Mϕ-T cell conjugates, where Mϕ CD39  
or CD73 were enriched in the immunological synapse. (c,D) Montage of 
synapse formation between a CD39+CD73− Mϕ and a Fluo-4-labeled 
autologous CD4+ T cell, where Mϕ CD39 was recruited to the immunological 
synapse (c) or not (D). Time was counted from the initial contact between 
the T cell and the Mϕ. In overlays, Fluo-4 (in pseudocolor; range is  
depicted on the right), CD39 (in green) and brightfield pictures are shown.  
(e) Quantification of mean calcium signals of engaged Fluo-4-loaded CD4+ 
T cells from (c,D) over time. Data represent mean values ± SEM of 20 or 45 
cells, respectively, calcium flux of which was traceable for >22 min. To 
statistically compare the traces, the area under curve (for fluxes 0–22 min) 
was calculated for each cell and groups were compared by unpaired 
two-tailed t-test; **p < 0.01.
13
Ohradanova-Repic et al. Adenosine-Mediated Switch of M-CSF-Dependent M1 Mϕs
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 852
Frβ+ Mϕs co-express cD39 and  
cD73 In Vivo
To investigate whether adenosine-producing Mϕs play a role 
in inflammatory processes in  vivo, we analyzed synovial fluid 
derived from patients with inflammatory arthritis by flow cyto-
metry (Figure  7A). CD16+MHCII−/lo granulocytes with weak 
CD39 expression represented the most abundant population in 
synovial fluid (Figures 7B,C). We used FRβ staining to discrimi-
nate between GM-CSF- and M-CSF-dependent monocytes/Mϕs 
(Figure  1A; Figure S1 in Supplementary Material) among the 
MHCII+CD11b+ cells. In line with our in vitro data, FRβ+ mono-
cytes/Mϕs expressed significantly higher levels of CD39, CD73 as 
well as CD163 than FRβ− monocytes/Mϕs (Figures 7C,D).
To further confirm our findings we analyzed myeloid cells 
from ankles of DBA/1JRj mice, in which we had induced arthritis 
using type II collagen (29). By co-staining with F4/80 and CD11b 
markers, we identified three distinct populations (Figure  7E): 
CD11bintF4/80int, CD11bhiF4/80hi, and CD11bhiF4/80lo cells, the 
latter most likely corresponding to granulocytes. CD11bintF4/80int 
Mϕs were most abundant and showed relatively low expression 
of FRβ and CD39 (Figure 7F). In contrast, CD11bhiF4/80hi Mϕs, 
which are known to be M-CSF-dependent (45), were highly posi-
tive for FRβ, and, similarly to the human M-CSF-dependent Mϕs 
they co-expressed CD39 and CD73 (Figure 7F).
Targeting of Frβ+cD39+cD73+ Mϕs  
With MTX alleviates arthritis
To ascertain whether adenosine produced by the FRβ+CD39+ 
CD73+ Mϕ subset is implicated in control of joint inflammation, 
we treated the collagen II-immunized DBA/1JRj mice before 
arthritis onset (starting day 14 and then every 3–4 days) with the 
folate antagonist MTX. MTX exhibits an anti-rheumatic effect 
through inhibition of several enzymes involved in nucleotide 
synthesis, leading to release of adenine nucleotides to the extra-
cellular space and their CD39 and CD73-dependent conver-
sion to adenosine (46–48). Indeed, upon MTX treatment, we 
observed a reduction in the clinical score (Figure 7G) that was 
accompanied by the reduction of all monitored populations, 
with the CD11bintF4/80int population affected the most by the 
MTX treatment (Figures  7H,I). In line with the in  vitro data 
(Figures 4F,G), we detected that MTX treatment caused CD73 
downregulation in all subsets, though only on the CD11bhiF4/80hi 
subset the difference was significant. Additionally, we observed 
that CD39 was also expressed at lower levels (Figures  7I,J). 
These data demonstrate that MTX treatment is able to control 
inflammation in the arthritic joints and normalizes expression of 
adenosine-producing enzymes CD39 and CD73.
MTX can be transported into cells by FRβ, but its affinity to 
the receptor is ≈50 times lower in comparison to the prime FRβ 
ligand, FA (49). To specifically target FRβ+CD39+CD73+ Mϕs 
with MTX, we coupled both MTX and FA to HSA as carrier 
(MTX-HSA-FA; Figure  7K). As controls, we used free MTX 
or MTX conjugated to HSA (MTX-HSA), and compared the 
clinical benefit of the three MTX formulations in the CIA model. 
PBS-treated control mice developed severe arthritis over time 
(Figure 7L). As seen previously, MTX significantly reduced the 
clinical score of the arthritic mice compared to PBS treatment. 
MTX efficacy was further improved, but not significantly, by its 
coupling to HSA, which is best explained by a better retention of 
the HSA conjugates within inflamed tissues (50). Strikingly, the 
MTX-HSA-FA conjugate improved significantly the clinical score 
of the treated mice compared to free MTX. On the last evaluation 
day, the mean arthritic score of the MTX-HSA-FA-treated mice 
was reduced to one-third or half, compared to the MTX-treated 
or MTX-HSA-treated mice, respectively. Altogether, specific 
targeting of the adenosine-producing FRβ+CD39+CD73+ Mϕs 
with MTX potently alleviates the clinical signs of arthritis in the 
CIA mouse model.
DiscUssiOn
Breaking self-tolerance leading to emergence of autoreactive 
T cells and autoantibodies is a hallmark of RA, suggesting that 
the disease is initiated by aberrant antigen presentation to T cells 
or aberrant antigen-specific T cell response (11, 51). Mϕs are the 
most abundant professional antigen-presenting cells in inflamed 
synovia (12), implying them as main drivers of pathogenic T cells. 
In the present study, we provide a comprehensive analysis of the 
interaction between Mϕs and T  cells, which provides valuable 
insights in the molecular causes underlying perpetuating inflam-
mation in RA-affected tissues. Based on our analysis, we also 
propose a therapeutic avenue to skew the balance toward resolu-
tion of inflammation (Figure 8).
To generate various Mϕ subtypes that resemble Mϕs present 
in RA tissues (12–16), and assess their effect onto T cell responses 
without contribution of bystander cells, we employed an in vitro 
coculture system of highly pure monocyte-derived Mϕs and 
autologous CD4+ T cells. We observed diametrically distinct Mϕ 
responses to proinflammatory stimuli (LPS + IFNγ), depending 
on the differentiation factor that was used for Mϕ generation. 
FigUre 6 | CD39 blockade by POM-1 mitigates the immunosuppressive phenotype of M-CSF-dependent LPS + IFNγ-activated macrophages (Mϕs).  
(a) Human Mϕs were differentiated for 7 days with GM-CSF or M-CSF and then activated for 2 days with LPS + IFNγ in the absence (control) or presence of  
20 µM POM-1. Expression of the cytokine genes was then analyzed by qRT-PCR. To compare gene expression, the data were normalized to the mRNA levels  
in the M-CSF LPS + IFNγ-stimulated Mϕs that were set to one. Data represent five different donors. Statistical significance was assessed by unpaired two-tailed 
t-test or one sample t-test in case of M-CSF Mϕs. (B) Mϕs from (a) were cocultured with autologous CD4+ T cells in the presence of the CD3 monoclonal antibody 
(mAb). After 2 days, T cells were stained for the activation markers CD69, CD25, and CD147 and analyzed by flow cytometry. Percentages ± SEM from activation 
marker-positive T cells from four experiments is given. (c) On day 5 of coculture, T cells were restimulated with phorbol 12-myristate 13-acetate and ionomycin for 
6 h and stained for IFNγ and IL-17A. Percentages ± SEM of the IFNγ- and IL-17A-expressing T cells of six independent experiments are shown. (D) Mϕs were 
differentiated for 7 days, activated for 2 days as indicated in the absence (control) or presence of 20 µM POM-1 and then cocultured with CFSE-labeled autologous 
CD4+ T cells stimulated (or not) with the CD3 mAb. Proliferation of T cells cocultured with non-treated Mϕs (filled gray histograms) or with the POM-1-pretreated 
Mϕs (open black histograms), respectively, was determined by quantifying the CFSE dilution after 7 days using flow cytometry. One representative of four 
experiments is shown. POM-1 pretreatment had no effect onto negligible proliferation of T cells in control cocultures without the CD3 mAb, thus these data are not 
shown. (e) The percentage of dividing T cells (from the parental population) cocultured with control or POM-1-pretreated Mϕs was calculated according to the CFSE 
peaks. (F) To determine the contribution of the CD39 blockade to the T cell proliferation, the division index of T cells cocultured with POM-1-pretreated Mϕs was 
normalized to the division index of respective T cells cocultured with control Mϕs. (e,F) Data represent means ± SEM of four independent experiments. Activation 
(B) and cytokine production (c) of the CD3 mAb-stimulated T cells was assessed by unpaired two-tailed t-test. Proliferation was statistically evaluated by two-way 
ANOVA with Bonferroni posttest (e) or one sample t-test (F), respectively; *p < 0.05, **p < 0.01, ***p < 0.001.
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While GM-CSF-differentiated Mϕs were highly proinflam-
matory, M-CSF-dependent Mϕs, which were marked by pro-
nounced and stable FRβ expression both in humans and mice, 
did not exhibit a classical M1 activation status, but rather a mixed 
M1/M2 phenotype seen also by others (52–54). Additionally, 
M-CSF-dependent LPS + IFNγ-stimulated Mϕs profoundly sup-
pressed T cells, which is widely considered a prominent feature of 
M2 Mϕs (55–57). We demonstrated that this suppressive activity 
toward T cells as well as the M1-to-M2 shift was caused by the 
alteration of the Mϕ purinergic pathway leading to production 
FigUre 7 | FRβhiCD39+CD73+ macrophages (Mϕs) are present in arthritic joints of man and mouse and their targeting with methotrexate (MTX) suppresses joint 
inflammation. (a) Gating strategy to identify innate immune cell populations in the knee synovial fluid from arthritis-affected patients analyzed by flow cytometry. 
Granulocytes were identified as CD16hiMHCII−/lo (black gate). MHCII+CD11b+CD14+ M-CSF-dependent monocytes/macrophages (Mo/Mϕs) were discriminated by 
prominent folate receptor β (FRβ) staining (red gate), while GM-CSF-dependent Mo/Mϕs were identified as FRβ− (blue gate). (B) Frequency of CD16hiMHCII−/lo 
granulocytes, FRβ− and FRβ+ Mo/Mϕs in the synovial fluid of arthritis-affected patients. Data represent mean ± SEM of three patients. (c) CD39 and CD73 
co-expression on granulocytes, FRβ− and FRβ+ Mo/Mϕs present in the synovial fluid of arthritis-affected patients. One representative staining of three patients is 
shown. (D) FRβ, CD39, CD73, and CD163 surface expression [measured as the geometric mean of fluorescence intensity (gMFI)] in the three populations was 
statistically evaluated. Data represent mean ± SEM of three experiments. (e) Cells, isolated from ankles of arthritic DBA/1JRj mice, were analyzed by flow cytometry 
using the forward and side-scatter characteristics and CD11b and F4/80 expression. Three distinct populations were identified: CD11bhiF4/80lo cells (black gate), 
CD11bintF4/80int Mϕs (blue gate), and CD11bhiF4/80hi Mϕs (red gate). (F) The populations were analyzed for FRβ (histogram on the left), CD39, and CD73 expression 
(contour plots on the right). (g) Clinical score of mice treated with PBS or MTX, respectively, on day 41. (h) Quantification of CD11bhiF4/80lo, CD11bintF4/80int, and 
CD11bhiF4/80hi subsets isolated from ankles of PBS- or MTX-treated arthritic mice [representative dot plots shown in (e,i)] within the forward and side-scatter gate 
[shown in (e), left]. (i) CD11bhiF4/80lo, CD11bintF4/80int, and CD11bhiF4/80hi populations from MTX-treated arthritic mice (dot plot on the left), and their FRβ 
(histogram in the middle), CD39 and CD73 expression (contour plot on the right). One representative of two similar experiments of 3 + 3 mice; where each ankle 
was analyzed separately. (J) FRβ, CD39, and CD73 surface expression (measured as gMFI) shown in (F,i) was statistically evaluated. Data represent mean ± SEM of 
3 + 3 mice with two ankles analyzed separately. (K) Conjugation strategy using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDAC) and 
N-hydroxysuccinimide (NHS), to create MTX-human serum albumin (HSA) conjugates (conjugation I) and MTX-HSA-folic acid (FA) conjugates (step I + II). (l) Mean 
clinical score (±SEM) of mice treated with various MTX formulations. Data are pooled from two independent experiments with 7–12 mice/group. The treatment and 
scoring in the second experiment was done one day earlier than in the first one. Statistical significance was assessed by one-way ANOVA (B,D), unpaired two-tailed 
t-test (g) and two-way ANOVA (h,J,l). *p < 0.05, **p < 0.01, ***p < 0.001.
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FigUre 8 | Working model—purinergic signaling differs in M-CSF- and GM-CSF-dependent macrophages (Mϕs): FRβ-targeted delivery of methotrexate (MTX) can 
restore homeostasis by boosting adenosine production in chronic inflammatory disorders. In rheumatoid arthritis (RA), Mϕs depending on Mϕ colony-stimulating 
factor (M-CSF) and expressing high levels of folate receptor β (FRβ) and CD39, in response to proinflammatory stimuli upregulate ATP-releasing channels pannexin-1 
(Panx1) and connexin-26 (Cx26) as well as the ectonucleotidase CD73. As a direct consequence, this Mϕ subset produces high levels of extracellular adenosine, 
which acts in an autocrine fashion through adenosine 2A receptors (A2ARs) to inhibit proinflammatory Mϕ responses. In particular, the release of proinflammatory 
cytokines (IL-6, IL-12, IL-23) is decreased while secretion of anti-inflammatory IL-10 is induced. Further, they suppress autoreactive T cells in a paracrine fashion. In 
contrast, adenosine production by the FRβ−/lo Mϕs, the prevalent Mϕ species in RA joints, is inadequate due to a markedly lower expression of Panx1 and Cx26 and 
much reduced co-expression of CD39 and CD73. Furthermore, this GM-CSF-dependent Mϕ subset expresses the adenosine 2B receptor (A2BR), which triggers 
upon recognition of adenosine IL-6 and IL-23 production, leading to an enhanced Th17 response. As a result, only FRβ-targeted delivery of MTX to 
FRβ+CD39+CD73+ Mϕs via a MTX-HSA-FA conjugate boosts adenosine-mediated immune suppression and restores homeostasis.
16
Ohradanova-Repic et al. Adenosine-Mediated Switch of M-CSF-Dependent M1 Mϕs
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 852
and response to extracellular adenosine. The first product of the 
purinergic pathway, extracellular ATP released in response 
to TLR ligands, has been considered proinflammatory due to 
P2X7-dependent activation of the NLRP3 inflammasome and 
subsequent IL-1β and IL-18 release (58). However, Cohen et al. 
showed that extracellular ATP in mouse Mϕs acted in an anti-
inflammatory manner due to the catabolic reaction provided by 
CD39 (40). We confirm and expand these data by showing that Mϕ 
CD39 is crucial for restraining early phases of T cell activation by 
local ATP degradation in the immunological synapse. However, 
CD39 degrades ATP to ADP and AMP only (37), and therefore, 
its catabolic activity must be paired with the AMP-degrading 
enzyme CD73, which we found to be upregulated by the proin-
flammatory stimuli and extracellular ATP, to efficiently produce 
adenosine. Mϕ-generated adenosine can then directly inhibit 
effector T cells by signaling through the high-affinity A2A receptor 
that mediates most of the immunosuppressive effects of adeno-
sine in immune cells by increasing intracellular cAMP (35, 37). 
Expression of the A2A receptor in T  cells is activation-induced 
(36, 42), which explains our observation that early T cell signaling 
was not entirely blocked, despite later inhibitory effects evidenced 
by lower expression of activation markers, cytokines and mark-
edly reduced proliferation.
In addition to the effect on T cells, Mϕ-generated adenosine can 
also shape Mϕ phenotype via autocrine signaling and the effects 
of exogenously added adenosine or specific receptor agonists are 
well documented [reviewed in Ref. (35, 37, 44)]. Adenosine A2A 
receptor stimulation inhibits TLR-mediated synthesis of TNF-α, 
IL-6 and IL-12, increases IL-10, VEGF, but also IL-1β (44, 59–63). 
On the other hand, signaling through the A2B receptor allevi-
ates TNF-α, IL-12 and potentiates IL-6 and IL-10 production 
(44, 64, 65). Alternatively, adenosine A1 and A3 receptor signaling 
leading to cAMP inhibition is thought to promote cell activation 
(35, 44). The cytokine profile of the immunosuppressive M-CSF-
dependent Mϕ subtype is in line with adenosine signaling through 
the A2A receptor, which we found highly expressed in response to 
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the proinflammatory stimuli. Our experiments with the CD39 
inhibitor POM-1 to block adenosine generation, resulting in 
increased IL12B and IL6 (and decreased IL10) strengthened this 
hypothesis. The downregulation of the other adenosine receptors 
and nucleoside transporters by this Mϕ subset might account for 
the bias toward the immunoregulatory phenotype.
Although FRβ− GM-CSF-differentiated Mϕs modulated expre-
ssion of several genes of the purinergic pathway in response to 
LPS + IFNγ, adenosine production by this subset was low, either 
due to poor co-expression of CD39 and CD73, as reported for 
non-suppressive memory T  cells (66, 67), or fast consumption 
through adenosine receptors and reuptake channels. POM-1-
mediated downregulation of IL6 expression further implied that 
GM-CSF-dependent Mϕs employed signaling via the A2B recep-
tor to enhance IL-6 levels upon stimulation with LPS + IFNγ, and 
skewed T cells in coculture experiments toward the Th17 lineage. 
In addition to IL6, POM-1 also inhibited IL23A expression in 
GM-CSF- and LPS + IFNγ-stimulated Mϕs, which together with 
IL-6 and either IL-1β or TGF-β, is necessary for the development 
of pathogenic Th17 cells (68, 69).
Interestingly, we found predominance of Mϕs with a phenotype 
similar to GM-CSF- and LPS + IFNγ-stimulated Mϕs (i.e., FRβ−/lo 
and non-overlapping expression of CD39 and CD73) in arthritis-
affected joints in both humans and mice. Based on our in vitro data, 
we presume that these Mϕs had developed in response to GM-CSF 
produced in high amounts by synovial CD4+ T cells (70). In humans, 
GM-CSF production is primarily linked to Th1 cells (70, 71). In mice, 
GM-CSF expression is directly confined to the Th17 subset (72, 73). 
Studies using autoimmune encephalomyelitis or myocarditis mouse 
models confirmed that GM-CSF produced by the Th17 subset is 
crucial for disease pathology by establishing a positive feedback 
loop via myeloid IL-23 and IL-6 that supports maintenance as 
well as de novo development of autoimmune Th17 cells (72–75). 
Therefore, it is not surprising that mice lacking Csf2, Il23a, Il6 and 
Il17 were shown to be protected from CIA (76–79), and blocking 
these genes or their receptors with mAbs is highly efficacious in 
RA patients enrolled in clinical trials (68, 80–82), in addition to the 
already approved IL6R mAb tocilizumab (82).
Based on our in vitro data, we propose that the balance between 
M-CSF- and GM-CSF-dependent Mϕ populations in tissues 
dictates whether the inflammation resolves through the action of 
adenosine or not. Indeed, in both humans and mice we observed 
that M-CSF-dependent FRβ+CD39+CD73+ Mϕs were present in 
arthritic joints at a low frequency and apparently were not suf-
ficient to counteract the proinflammatory acti vity of the FRβ−/lo 
GM-CSF-dependent Mϕs. Similarly, also the MTX treatment of 
our CIA mice was not able to completely suppress inflammation. 
It is conceivable that MTX is taken up by GM-CSF-dependent 
Mϕs via the highly expressed reduced folate carrier/Slc19a1 
(83,  84), and then promotes as a consequence inflammation 
through upregulation of IL6 and IL23A. Therefore, only folate-
directed delivery of MTX through the HSA-MTX-FA conjugate 
into adenosine-producing FRβ+CD39+CD73+ Mϕs was able 
to control the inflammation in the CIA model. These data are 
further supported by our recent results showing that mice treated 
with folate-functionalized liposomes with MTX shielded in the 
liposome cavity were completely protected from CIA (29).
In conclusion, we have demonstrated that extracellular purine 
metabolism governs the switch from the proinflammatory to the 
suppressive Mϕ phenotype. This newly discovered mechanism 
provides a rationale for specific targeting of the purine metabo-
lism by modulating drugs, such as MTX, in order to fully resolve 
Mϕ-driven diseases including inflammation of RA.
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MOVie s1 | Related to Figure 5c. Live cell imaging of the human CD4+ 
T cell interaction with an autologous CD39+CD73− M-CSF-differentiated and 
LPS + IFNγ-activated macrophage (Mϕ), which showed enriched expression 
of CD39 in the immunological synapse over time. Time-lapse microscopy of 
Mϕ-expressed CD39 (shown in green), its recruitment to the synapse and T cell 
calcium flux monitored by Fluo-4 fluorescence (in pseudocolor; range is depicted 
in Figure 5c) over time. Images were acquired every minute for 45 min.
MOVie s2 | Related to Figure 5D. Live cell imaging of the human CD4+ 
T cell interaction with an autologous CD39+CD73− M-CSF-differentiated 
and LPS + IFNγ-activated macrophage (Mϕ), which did not show enriched 
expression of CD39 in the immunological synapse over time. Images were 
acquired every minute for 43 min. CD39 staining on the M-CSF-differentiated 
and LPS + IFNγ-activated Mϕ is shown in green, while fluorescent calcium 
sensor Fluo-4 in T cells is shown in pseudocolor.
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